electroCore (Nasdaq: ECOR) announced online publication in Neuromodulation of a randomized study evaluating non-invasive nerve stimulation for Long COVID. The four-week study compared cervical vagus nerve stimulation, Sonocea’s acoustic stimulation, their combination and monitoring alone. Of 541 enrolled participants, 250 met final analysis criteria.Depressive symptom scores decreased approximately 33% with electroCore’s technology, 31% with Sonocea’s and 34% with both, versus approximately 2% with monitoring alone. Each active group improved significantly from baseline; changes over time differed significantly across groups. Active treatments also showed improvements across other symptom domains. Direct comparisons found no significant differences among active treatments. Findings are hypothesis-generating: the study was open-label, lacked a sham control and relied primarily on patient-reported outcomes.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Cyclone Arnab has flooded key rail bridges on the Howrah–Chennai line, stranding thousands of passengers as East Coast Railway enforces large-scale cancellations and diversions.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

electroCore (Nasdaq: ECOR) submitted a 510(k) notification to the FDA seeking clearance of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN).The submission draws on 168 subjects in a randomized controlled trial and an open-label study. Neuropathic pain scores decreased approximately 40% with active treatment versus approximately 24-33% with sham treatment. A non-pre-specified analysis of subjects with moderate to severe baseline pain showed decreases of approximately 50% versus approximately 30%.In the 142-subject randomized trial, neuropathy questionnaire scores improved 11.6% with Quell versus 8.7% with sham, meeting the preliminary study’s pre-specified statistical significance threshold of 0.2. In the open-label study, 22 completers showed 13% improvement over six weeks. Quell-related adverse events were generally infrequent, mild and self-limiting. FDA clearance remains pending.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

YouTube video by UNDER17 - Topic